Clinical trials: Ritonavir
Amyotrophic Lateral Sclerosis
HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Background: Some people with Amyotrophic Lateral Sclerosis (ALS) have a high level of the virus HERV-K in their blood. Researchers do not think this virus causes ALS.
- Trial name
- NCT02437110
- Testing
- Darunavir, Ritonavir, Dolutegravir
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Pneumonia, Viral, Cytokine Storm
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19
The host response against the coronavirus 2 (SARS-CoV-2) appears to be mediated by a 'cytoquine storm' developing a systemic inflammatory mechanism and an acute respiratory distress syndrome (ARDS), in the form of a bilateral…
- Trial name
- ULTRA-COVID (NCT04394182)
- Testing
- Ultra-Low-dose radiotherapy, ventilatory support with oxygen therapy, Lopinavir/ritonavir
- Where
- 2 sites in Spain
- Volunteers
- 15 people
- Sponsor
- Fundacion GenesisCare
Hepatitis C Virus
The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
This study seeks to assess the durability of response and persistence of resistance to ombitasvir/ paritaprevir/ritonavir in Japanese participants who enrolled in a Phase 2 or 3 clinical study with these agents for the treatment…
- Trial name
- NCT02581020
- Where
- 53 sites in Japan
- Volunteers
- 344 people
- Sponsor
- AbbVie
Acquired Immunodeficiency Syndrome, HIV Infections
CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes
Therapy guidelines recommend the use of either the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz or a ritonavir-boostered protease inhibitor (PI) plus 2 nucleoside reverse transcriptase inhibitors (NRTI) as…
- Trial name
- NCT00966160
- Testing
- Lopinavir/Ritonavir plus Lamivudine/Zidovudine, Efavirenz plus Lamivudine/Zidovudine
- Where
- Germany
- Volunteers
- 215 people
- Sponsor
- University of Cologne
Hepatic Insufficiency
Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency
To determine the pharmacokinetics of single-dose and steady-state Tipranavir/Ritonavir (TPV/r) 500/200 mg in subjects with mild to moderate hepatic insufficiency
- Trial name
- NCT02249442
- Testing
- Tipranavir (TPV), Ritonavir (r)
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
HIV/AIDS, HIV Infections
Treatment Options for Protease Inhibitor-exposed Children
The investigators hypothesize that switching to a regimen based on efavirenz will be as effective and safe as remaining on a regimen based on Lopinavir/ritonavir for HIV-infected children.
- Trial name
- NEVEREST-III (NCT01146873)
- Testing
- Efavirenz (EFV), Lopinavir/ritonavir (LPV/r), Stavudine (D4T)
- Where
- South Africa
- Volunteers
- 300 people
- Sponsor
- Columbia University
HIV Infections
Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding
The ANRS 12174 study is a clinical trial that will compare the efficacy and safety of prolonged infant peri-exposure prophylaxis (PEP) with Lopinavir/Ritonavir (LPV/r) versus Lamivudine to prevent HIV-1 transmission through…
- Trial name
- NCT00640263
- Testing
- lopinavir/ritonavir (LPV/r), Lamivudine (3TC)
- Where
- 4 sites in Burkina Faso, South Africa and 2 more
- Volunteers
- 1,500 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Chronic Hepatitis C
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus
The purpose of this study is to explore the efficacy and safety of TMC647055, TMC435, and low-dose ritonavir, administered together with and without ribavirin and of TMC647055, TMC435, low-dose ritonavir administered together…
- Trial name
- NCT01724086
- Testing
- TMC647055, TMC435, Ritonavir
- Where
- 10 sites in Belgium, Germany
- Volunteers
- 90 people
- Sponsor
- Janssen R&D Ireland
Atazanavir
Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers
Compared to those of Caucasians, the plasma levels of atazanavir (ATV) may be higher in Koreans with the same dosage regimen(s).
- Trial name
- NCT01368783
- Testing
- atazanavir, Atazanavir(ATZ) and Tenofovir(TDF), Atazanavir(ATZ) + Ritonavir
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
COVID-19, SARS-CoV-2
Treatment for COVID-19 in High-Risk Adult Outpatients
This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the…
- Trial name
- NCT04354428
- Testing
- Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin
- Where
- 6 sites in United States
- Volunteers
- 289 people, healthy volunteers welcome
- Sponsor
- University of Washington
2019-nCoV
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
Base on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in patients with 2019-nCoV pneumonia.
- Trial name
- NCT04261907
- Testing
- ASC09/ritonavir group, lopinavir/ritonavir group
- Where
- China
- Volunteers
- 6 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
HIV Infections
Breastfeeding, Antiretroviral, and Nutrition Study
This is a comparative clinical trial among HIV-infected women and their infants to determine: 1. the benefit of nutritional supplementation given to women during breastfeeding 2.
- Trial name
- NCT00164736
- Testing
- Maternal zidovudine/lamivudine/lopinavir-ritonavir, Infant nevirapine, Maternal protein and calorie supplement
- Where
- Malawi
- Volunteers
- 2,369 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
HIV-1 Infections
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
This post-marketing observational study is conducted for obtaining data on clinical, biological and virological outcomes, compliance and tolerability of using a lopinavir/ritonavir (LPV/r) -containing regimen for the treatment of…
- Trial name
- NCT01074931
- Testing
- Lopinavir/ritonavir (Kaletra)
- Where
- 5 sites in China
- Volunteers
- 98 people
- Sponsor
- Abbott
COVID-19
Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection
Evaluation of the efficacy and safety of Ganovo combined with ritonavir for patients infected with SARS-CoV-2.
- Trial name
- NCT04291729
- Testing
- Ganovo+ritonavir+/-Interferon nebulization
- Where
- China
- Volunteers
- 11 people
- Sponsor
- The Ninth Hospital of Nanchang
Liver Transplantation
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
The study aimed to present our experience in treating recurrent HCV genotype 4 infection post living donor liver transplantation (LDLT) since introduction of the second generation direct acting antiviral drugs (DAAs) in Egypt.
- Trial name
- NCT03133065
- Testing
- treatment of HCV with oral direct acting antiviral therapy
- Volunteers
- 89 people
- Sponsor
- Ain Shams University
HIV Infections
Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients
A 2-year multicenter, phase II/III, randomized active-controlled trial to evaluate the efficacy and tolerance of two maintenance strategies in HIV-1 infected patients with HIV RNA below 50 copies/mL : a monotherapy with…
- Trial name
- ANRS 140 DREAM (NCT00946595)
- Testing
- efavirenz/emtricitabin/tenofovir, lopinavir/ritonavir
- Where
- France
- Volunteers
- 420 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
COVID-19
FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals
The current pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with first presentation of symptoms…
- Trial name
- FLARE (NCT04499677)
- Testing
- Favipiravir, Lopinavir/ Ritonavir
- Where
- 2 sites in United Kingdom
- Volunteers
- 240 people
- Sponsor
- University College, London
Human Immunodeficiency Virus, Treatment
First in Human Study of TLC-ART 101 (ACTU 2001)
This study is a prospective, open-label, single-site, first-in-human study of a long-acting, injectable combination antiretroviral therapy platform, with a pharmacologically-guided adaptive design for dose escalation…
- Conditions
- Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
- Trial name
- NCT05850728
- Testing
- TLC-ART
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV-1 Infection
Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
The goal of antiretroviral therapy should be maintaining undetectable plasma viral load, only present condition to prevent the progression of the disease, improve immune restoration and prevent the emergence of viral resistance…
- Trial name
- ATALOW (NCT02473328)
- Testing
- Atazanavir 200 mg/r
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HIV
Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
Lopinavir/ritonavir monotherapy is currently a well known and widely used strategy, while Lopinavir/ritonavir 800/200 mg once a day in a triple-therapy was approved a few years ago.
- Trial name
- NCT01581853
- Testing
- Lopinavir/ritonavir 800 mg / 200mg
- Where
- 2 sites in Spain
- Volunteers
- 21 people
- Sponsor
- Daniel Podzamczer